RCAMU
HRTX icon

Rothschild & Co Asset Management US’s Heron Therapeutics HRTX Stock Holding History

Rothschild & Co Asset Management US’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,379,846
Closed -$12.6M – 275
2021
Q4 		$12.6M Buy
1,379,846
+305,321
+28% +$3.12M 0.15% 153
2021
Q3 		$11.5M Sell
1,074,525
-39,268
-4% -$478K 0.14% 168
2021
Q2 		$17.3M Buy
1,113,793
+75,998
+7% +$1.21M 0.21% 139
2021
Q1 		$16.8M Sell
1,037,795
-314,959
-23% -$5.61M 0.21% 141
2020
Q4 		$28.6M Sell
1,352,754
-257,845
-16% -$4.48M 0.37% 83
2020
Q3 		$23.9M Buy
1,610,599
+1,102,196
+217% +$17.2M 0.43% 90
2020
Q2 		$7.48M Buy
508,403
+6,416
+1% +$105K 0.11% 238
2020
Q1 		$5.89M Buy
501,987
+462,236
+1,163% +$8.69M 0.09% 245
2019
Q4 		$934K Sell
39,751
-1,841
-4% -$40.7K 0.01% 321
2019
Q3 		$769K Buy
41,592
+3,805
+10% +$70K 0.01% 324
2019
Q2 		$702K Buy
37,787
+9,267
+32% +$185K 0.01% 330
2019
Q1 		$697K Sell
28,520
-24,602
-46% -$644K 0.01% 340
2018
Q4 		$1.38M Sell
53,122
-385
-0.7% -$10.6K 0.02% 339
2018
Q3 		$1.69M Buy
+53,507
New +$1.99M 0.02% 343

Other funds holding HRTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Rothschild & Co Asset Management US's HRTX Position: Q1 2022 in Review

Rothschild & Co Asset Management US sold out of Heron Therapeutics (HRTX) in Q1 2022, closing a stake of 1,379,846 shares — an estimated $12.6M sold.

Rothschild & Co Asset Management US first reported a position in HRTX in Q3 2018 and held it in 14 quarters. The position peaked at $28.6M in Q4 2020. 186 funds tracked by Wall St. Rank hold HRTX as of Q1 2022.

  • Rothschild & Co Asset Management US reported no remaining Heron Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 1,379,846 Heron Therapeutics shares in Q1 2022, an estimated $12.6M.
  • Rothschild & Co Asset Management US first reported a position in Heron Therapeutics in Q3 2018 and held it in 14 quarters.
  • Rothschild & Co Asset Management US's Heron Therapeutics position peaked at $28.6M in Q4 2020.
  • 186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2022.

Based on Rothschild & Co Asset Management US's 13F filing for Q1 2022, filed 13 May 2022.